Vaccines
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
Laura L Hammitt, Ulrike K Buchwald, Jennifer McCauley, Tulin Shekar, Wei Fu, Kyeongmi Cheon, Tina Sterling, Gretchen Tamms, Natalie Banniettis, Luwy Musey, Jason J LeBlanc, Robert Weatherholtz, Dennie Parker Riley, Estar Denny, Carol Tso
Published: 202510.3390/vaccines14010003
Abstract
BACKGROUND/OBJECTIVES: American Indian/Alaska Native individuals exhibit a higher prevalence of carriage of Streptococcus pneumoniae and are at increased risk of invasive pneumococcal disease compared with the general US population, driven by persist…
Preview only. Read the full abstract at the source